Tysabri and PML: What to Know About the FDA Warning

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Specific Risk Assessment

If you or a loved one takes Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established that this rare brain infection is a known complication of natalizumab therapy, with risk factors that include JC virus antibody status and duration of treatment. This page explains the FDA label context, what monitoring involves, and what the science says about long-term outcomes.

Tysabri and PML: A Direct Link

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus. The prognosis for patients who develop PML while on Tysabri is poor, with the condition usually leading to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This narrative examines the permanence of PML from Tysabri, drawing on evidence from the FDA-approved prescribing information. PML is a serious and often irreversible condition. The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, which 'usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This language indicates that the damage caused by PML is typically permanent, as the infection destroys oligodendrocytes, the cells that produce myelin in the central nervous system. The resulting demyelination is generally not reversible, leading to lasting neurological deficits. While some patients may survive PML, they often experience significant residual impairments, such as cognitive decline, motor dysfunction, or visual loss, which can be permanent.

Timeline and Risk Factors for PML Development

The timeline between Tysabri exposure and the development of PML varies. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks, and these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data suggest that PML can develop after varying durations of therapy, with longer treatment duration, especially beyond two years, identified as a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has also been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation. The prescribing information advises that patients should continue to be monitored for any new signs or symptoms that may be suggestive of PML for at least six months following discontinuation of Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that the risk of PML can persist even after stopping the drug, and the condition may manifest later, further complicating prognosis.

Mechanism and Warning Adequacy

The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking the adhesion of immune cells to the blood-brain barrier. This reduces the migration of lymphocytes into the central nervous system, which is beneficial for treating inflammatory conditions like multiple sclerosis and Crohn's disease. However, this immunosuppressive effect in the brain impairs immune surveillance against the JC virus, allowing the virus to reactivate and cause PML in susceptible individuals. The risk factors for PML include the presence of anti-JCV antibodies, longer treatment duration, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Regarding the adequacy of warnings, the prescribing information includes a boxed warning that clearly states the risk of PML and its severe outcomes. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that the benefits of treatment outweigh the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These measures indicate that the warnings are comprehensive, but the prognosis for affected patients remains poor.

Conclusion: Permanence of PML from Tysabri

In summary, PML from Tysabri is generally permanent, with most patients experiencing death or severe disability. The timeline for PML development can range from months to years of therapy, and the risk persists even after discontinuation. The mechanistic link is through impaired immune surveillance in the brain, and the warnings in the prescribing information are robust. However, the irreversible nature of the neurological damage underscores the seriousness of this adverse event.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Is Progressive Multifocal Leukoencephalopathy from Tysabri permanent?

Yes, PML from Tysabri is generally permanent. The infection destroys oligodendrocytes, leading to irreversible demyelination and lasting neurological deficits. Most patients experience death or severe disability, and survivors often have permanent impairments such as cognitive decline, motor dysfunction, or visual loss.

What is the prognosis for patients who develop PML while on Tysabri?

The prognosis is poor. The prescribing information states that PML 'usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). While some patients may survive, they typically experience significant residual impairments that are permanent.

Can PML develop after stopping Tysabri?

Yes, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation. Patients should be monitored for at least six months after stopping Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.